MX2021010135A - Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona. - Google Patents

Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.

Info

Publication number
MX2021010135A
MX2021010135A MX2021010135A MX2021010135A MX2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A
Authority
MX
Mexico
Prior art keywords
disorder
relacorilant
grm
heteroaryl
fused azadecalin
Prior art date
Application number
MX2021010135A
Other languages
English (en)
Inventor
Andreas Moraitis
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2021010135A publication Critical patent/MX2021010135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos y composiciones para diagnosticar a un paciente sospechoso de padecer de, y para tratar un paciente que padece de, un trastorno tal como hipercortisolemia, síndrome metabólico, pre-diabetes, diabetes, síndrome de Cushing, enfermedad de Cushing, hiperglicemia secundaria a hipercortisolemia, una enfermedad hepática, un trastorno cardiaco, presión arterial alta, un trastorno de la coagulación sanguínea, un cáncer, un trastorno psicológico, aumento de peso, un trastorno de control de glucosa, un trastorno óseo (por ejemplo, osteoporosis), hipogonadismo, pseudoacromegalia, tumores hipofisarios, hipercortisolismo funcional, Tumores Secretores de ACTH, neuropatía periférica, dislipidemia y otros trastornos. Los métodos y composiciones incluyen la administración de un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona (GRM). El GRM de azadecalina fusionada con heteroaril-cetona preferido es ((R)-(1-(4-fluorofeni l)-6-((1-metil-1H-pirazol-4-il)sulfonil)-4,4a,5,6,7,8-hexahidro-1 H-pirazolo[3,4-g]isoquinolin-4a-il)(4-(trifluorometil)piridin-2-i l)metanona) relacorilante. En algunos casos, el GRM (por ejemplo, relacorilante) se administra oralmente. En algunos casos, el GRM (por ejemplo, relacorilante) se administra oralmente sin comida.
MX2021010135A 2019-02-22 2020-02-21 Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona. MX2021010135A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962809327P 2019-02-22 2019-02-22
US201962814441P 2019-03-06 2019-03-06
US201962833517P 2019-04-12 2019-04-12
PCT/US2020/019167 WO2020172501A1 (en) 2019-02-22 2020-02-21 Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Publications (1)

Publication Number Publication Date
MX2021010135A true MX2021010135A (es) 2021-09-23

Family

ID=72141382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010135A MX2021010135A (es) 2019-02-22 2020-02-21 Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.

Country Status (14)

Country Link
US (4) US11058670B2 (es)
EP (1) EP3927345A4 (es)
JP (2) JP2022523376A (es)
KR (1) KR20210118971A (es)
CN (1) CN113490496A (es)
AU (1) AU2020226863B2 (es)
BR (1) BR112021015129A2 (es)
CA (1) CA3131263C (es)
CL (1) CL2021002145A1 (es)
IL (1) IL285771A (es)
MX (1) MX2021010135A (es)
SG (1) SG11202108964YA (es)
WO (1) WO2020172501A1 (es)
ZA (1) ZA202105633B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP7218438B2 (ja) 2018-12-19 2023-02-06 コーセプト セラピューティクス， インコーポレイテッド レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物
KR20210095939A (ko) * 2018-12-21 2021-08-03 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 투여에 의한 쿠싱 증후군의 과응고병증의 치료
SG11202108964YA (en) 2019-02-22 2021-09-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP4157274A4 (en) * 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated CONCURRENT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACTORILANTS AND CYP2C9 SUBSTRATES
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
WO2023225282A1 (en) * 2022-05-20 2023-11-23 Corcept Therapeutics Incorporated Methods of treating cushing's syndrome and liver disorders, and of reducing liver toxicity of other drugs administered to a patient
WO2024077169A1 (en) * 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
WO2024118735A1 (en) * 2022-11-30 2024-06-06 Corcept Therapeutics Incorporated Treatments for cushing's syndrome that do not significantly affect cardiac rhythms

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (es) 1954-11-30 1957-04-11
CA1270488A (en) 1983-09-26 1990-06-19 John M. Schaus Pyrazole-ring alkylated pyrazoloquinolines and intermediates
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
ES2173921T3 (es) 1993-08-06 2002-11-01 Glaxosmithkline Spa Derivados de hidroisoquinolina.
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP1061919A4 (en) 1998-03-10 2002-09-04 Res Triangle Inst NEW OPIATES, METHOD FOR THE PRODUCTION AND USE THEREOF
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
US20020115613A1 (en) 2001-02-16 2002-08-22 Kumar M. Vijay Treatment of prostate cancer
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
MXPA04000692A (es) 2001-07-23 2004-04-21 Corcept Therapeutics Inc MeTODOS PARA EVITAR GANANCIA DE PESO INDUCIDA ANTISICOTICA.
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004004653A2 (en) 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferon-alpha therapy
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
CA2552419C (en) 2004-01-09 2013-04-23 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
EP1723174A1 (en) 2004-02-26 2006-11-22 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health A novel modulator of glucocorticoid receptor activities
NZ550362A (en) 2004-03-09 2010-06-25 Corcept Therapeutics Inc Fused ring azadecalin glucocorticoid receptor modulators
AU2006232660B2 (en) * 2005-04-05 2010-03-25 F. Hoffmann-La Roche Ag 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
ES2448839T3 (es) 2007-11-01 2014-03-17 Bristol-Myers Squibb Company Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
SG185952A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
US8461172B2 (en) 2009-05-12 2013-06-11 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
KR20130106378A (ko) 2010-08-27 2013-09-27 코어셉트 쎄라퓨틱스, 잉크. 피리딜-아민 융합된 아자데칼린 조절제
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
PL3329919T3 (pl) 2011-11-11 2020-05-18 Gilead Apollo, Llc Inhibitory ACC i ich zastosowania
US9289436B2 (en) 2012-02-24 2016-03-22 The University Of Chicago Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
ES2930298T3 (es) * 2012-05-25 2022-12-09 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
ES2869172T3 (es) * 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
WO2016140867A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
BR112018067330A2 (pt) 2016-03-01 2019-01-22 Corcept Therapeutics Inc método para o tratamento de paciente com carga tumoral
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US20180325891A1 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
KR20210095939A (ko) * 2018-12-21 2021-08-03 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 투여에 의한 쿠싱 증후군의 과응고병증의 치료
SG11202108964YA (en) 2019-02-22 2021-09-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Also Published As

Publication number Publication date
US12097192B2 (en) 2024-09-24
US20230131372A1 (en) 2023-04-27
JP2022523376A (ja) 2022-04-22
CA3131263A1 (en) 2020-08-27
KR20210118971A (ko) 2021-10-01
SG11202108964YA (en) 2021-09-29
US20230346756A1 (en) 2023-11-02
WO2020172501A1 (en) 2020-08-27
JP2024009951A (ja) 2024-01-23
US20210338643A1 (en) 2021-11-04
US11684612B2 (en) 2023-06-27
ZA202105633B (en) 2023-02-22
US20200268723A1 (en) 2020-08-27
AU2020226863A1 (en) 2021-08-12
CL2021002145A1 (es) 2022-01-28
CN113490496A (zh) 2021-10-08
CA3131263C (en) 2024-01-02
EP3927345A1 (en) 2021-12-29
EP3927345A4 (en) 2022-12-21
US11590113B2 (en) 2023-02-28
US11058670B2 (en) 2021-07-13
BR112021015129A2 (pt) 2021-09-28
AU2020226863B2 (en) 2023-04-06
IL285771A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2021010135A (es) Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.
CN101980708B (zh) 作为vegf驱动的血管生成过程的有效调节剂的咪唑并喹啉类及嘧啶衍生物
EA018839B1 (ru) Замещенные производные 2,3-дигидроимидазо[1,2-с]хиназолина, полезные для лечения гиперпролиферативных нарушений и болезней, связанных с ангиогенезом
US8470811B2 (en) Substituted heterocyclylbenzylpyrazoles and use thereof
EA027476B1 (ru) Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости
US20150328188A1 (en) Combination Therapies for the Treatment of Proliferative Disorders
WO2010054764A1 (de) Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
UA128348C2 (uk) Сполуки для лікування кіназозалежних розладів
CN115667255A (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
CN107530304A (zh) Olig2活性的抑制
CN108586443B (zh) 一种防治支气管肺癌的药物及其制备方法
CN102834100A (zh) 新型pan-CDK抑制剂用于治疗肿瘤的用途
US20090048292A1 (en) Synergistic combination
KR102102109B1 (ko) N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
CN108349900A (zh) 雄激素受体拮抗剂
JP6746794B2 (ja) 重水素化３−（４，５−置換アミノピリミジン）フェニル誘導体及びその使用
CN110087653A (zh) 用于治疗肺高血压的组合疗法
DK2914264T3 (en) 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR USE FOR THE TREATMENT OF HEPATOCELLULAR CARCINOM (HCC)
KR20100021444A (ko) 플루오로퀴놀론을 사용하여 염증을 조절하기 위한 조성물 및 방법
US9980966B2 (en) Combinations of cancer therapeutics
US20240024324A1 (en) Kinase inhibitor combinations for cancer treatment
Allison et al. Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model
AU2021256476A1 (en) Benzimidazole compound for the treatment of metabolic disorders